INS and hyperlipidemia: Bioactive fraction significantly improved hyperglycemia and hyperlipidemia in type 2 diabetic rats caused by HFD and a low dose of STZ, as shown by a significant decrease in body weight loss, FBG level, enhancing glucose tolerance, regulated lipid metabolism, and mitigated insulin resistance in vivo.